Integrated Metagenomic and Metabolomic Core

综合宏基因组和代谢组核心

基本信息

批准号：
10685510
负责人：
SHIRISH S BARVE
金额：
$ 36.58万
依托单位：
VANDERBILT UNIVERSITY MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-10 至 2026-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10685510
关键词：
Affect Aging Alcohol consumption Alcohols Bile Acids Bioinformatics Biological Specimen Banks Boston Cardiovascular Diseases Cessation of life Clinical Cohort Studies Collaborations Communities Complement Computational algorithm Data Data Analyses Development Ensure Equipment and supply inventories Evaluation Fostering Generations Genes Goals HIV HIV Infections HIV/AIDS Heavy Drinking Human Resources Infrastructure Institution Letters Logistics Longitudinal Studies Longitudinal, observational study Mass Fragmentography Medicine Metagenomics Methods Molecular Monitor National Cancer Institute National Institute on Alcohol Abuse and Alcoholism Nomenclature Outcome Output Participant Persons Plasma Preparation Probiotics Procedures Publishing Quality Control RNA Recording of previous events Research Design Research Personnel Research Project Grants Resources Role Russia Sampling Sampling Studies Serum Shipping Shotguns Site Specimen Standardization Taxon Techniques Therapeutic Uganda Universities Veterans Volatile Fatty Acids Work alcohol research biobank clinical care cohort college comorbidity data integration data management data mining data repository data sharing data standards dysbiosis efficacy evaluation gut bacteria gut dysbiosis gut microbiota host microbiota improved innovation metabolome metabolomics metagenomic sequencing microbial microbiome microbiome research microbiota probiotic supplementation programs rRNA Genes randomized, clinical trials sample collection trimethyloxamine whole genome

项目摘要

The Integrated Metagenomics and Metabolomics Core (IMMC) will provide a platform that interconnects Projects 1 and 2. Specifically, IMMC will provide high-quality, metagenomics and targeted metabolomics data, to be integrated with the probiotics randomized clinical trial and clinical cohort outcomes for Projects 1 and 2, respectively. The IMMC has already acquired relevant metagenomics and metabolomics data (see Preliminary data sections E1.2 and F.1.A.2) that supports the experimental rationale and study design for Projects 1 and 2. To ensure optimal scientific output from the study samples, the IMMC has implemented standardized procedures for collection of samples from Projects 1 and 2 study sites, and established logistics to coordinate shipment of samples for analysis, manage inventory, and enable tracking of chain of custody. For Project 1, IMMC - sub-core 1 will conduct state of the art metagenomics analysis of fecal samples collected from study participants receiving probiotics supplementation, to profile the changes in the gut microbial communities. The culture- independent molecular methods will consist of 16S rRNA gene and whole genome shotgun (WGS) metagenomic sequencing that provide the most comprehensive microbiota profiling. Rigorous sequence data analysis will utilize a set of advanced computational algorithms, according to taxon- based or function-based data matrices. IMMC- sub-core 2 will conduct targeted metabolomics analysis of plasma/serum (Projects 1 and 2) to monitor host and gut-microbiota metabolomes. The IMMC will collaborate with Projects to develop meaningful study designs, implement effective sample collection and storage strategies, generate high-quality metagenomics and targeted metabolomics data, computationally summarize these data and support interpretation of the results. It will implement high-quality techniques, along with quality control standards, that produce meaningful results in a timely fashion. The IMMC will also standardize data generation methods across studies to enable integration across Projects and uncover robust discoveries. To accomplish these goals the IMMC has established the following aims: 1. Employ metagenomic approaches to generate and analytically summarize project microbiome data. 2. Perform targeted metabolomics analyses to profile plasma/serum metabolites. 3. Manage specimen and data biorepository and facilitate transfer between research Projects.

综合宏基因组学和代谢组学核心（IMMC）将提供一个互连的平台项目1和2。具体而言，IMMC将提供高质量的宏基因组学和靶向代谢组学数据，与项目 1 和 2 的益生菌随机临床试验和临床队列结果相结合，分别。 IMMC已经获得了相关的宏基因组学和代谢组学数据（见初步数据）数据部分 E1.2 和 F.1.A.2）支持项目 1 和 2 的实验原理和研究设计。为了确保研究样本获得最佳科学输出，IMMC 实施了标准化从项目 1 和 2 研究地点收集样本的程序，并建立后勤协调运送样品进行分析、管理库存并实现监管链跟踪。对于项目 1，IMMC - 子核心 1 将对粪便样本进行最先进的宏基因组分析从接受益生菌补充剂的研究参与者中收集数据，以分析肠道的变化微生物群落。不依赖于培养物的分子方法将包括 16S rRNA 基因和完整的基因组鸟枪法 (WGS) 宏基因组测序可提供最全面的微生物群分析。根据分类标准，严格的序列数据分析将利用一套先进的计算算法基于或基于函数的数据矩阵。 IMMC-子核心2将进行靶向代谢组学分析血浆/血清（项目 1 和 2）用于监测宿主和肠道微生物代谢组。 IMMC 将与项目合作开发有意义的研究设计，实施有效的样本收集和存储策略，生成高质量的宏基因组学和目标代谢组学数据，通过计算总结这些数据并支持结果的解释。它将高质量实施技术以及质量控制标准，及时产生有意义的结果。内蒙古医学中心还将标准化跨研究的数据生成方法，以实现跨项目和发现强有力的发现。为了实现这些目标，IMMC 制定了以下目标： 1. 采用宏基因组方法生成并分析总结项目微生物组数据。 2. 进行靶向代谢组学分析以分析血浆/血清代谢物。 3. 管理样本和数据生物存储库并促进研究项目之间的转移。